Cleveland Clinic-led study: Rivaroxaban reduced blood clots and related death in cancer patients

(Cleveland Clinic) Cleveland Clinic medical oncologist and researcher, Alok Khorana, M.D., is the primary investigator on a study that concluded rivaroxaban for venous thromboembolism (VTE), a blood clot in the venous system, significantly reduced VTE and VTE-related death for outpatient, at-risk cancer patients while they were taking the oral blood thinner.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news